The present invention relates to novel isoxazoline-indole derivatives
according to Formula (I), a pharmaceutically acceptable acid or base
addition salt thereof, a stereochemically isomeric form thereof, an
N-oxide form thereof or a quaternary ammonium salt thereof, with a
binding affinity towards dopamine receptors, in particular towards
dopamine D.sub.2 and/or D.sub.3 receptors, with selective serotonin
reuptake inhibition (SSRI) properties and showing an affinity for the
5-HT.sub.1A receptor, pharmaceutical compositions comprising the
compounds according to the invention, the use thereof for the prevention
and/or treatment of a range of psychiatric and neurological disorders, in
particular certain psychotic disorders, most in particular schizophrenia
and processes for their production, wherein the variables are further
defined in the application.